...
首页> 外文期刊>Materials science & engineering >Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid
【24h】

Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid

机译:通过全反式视黄酸增强的叶酸受体介导的仿生染色白蛋白纳米颗粒的高效肿瘤靶向递送siRNA

获取原文
获取原文并翻译 | 示例
           

摘要

Acute myeloid leukemia (AML) is the most universal type and fatal disease of hematological malignancy, with poor outcomes despite chemotherapy and bone marrow transplantations. Benefited from the narrow tissue specificity of folate receptor beta (FR beta) aberrantly expressed on hematological linage cell lines, NPs modified with folate acid (FA) has been widely applied for crossing cell membrane barriers in FR-targeted therapies for AML. Thus, the biomimetic nanoparticles (NPs) mediated by FR beta were conducted by an albumin modifier as previously synthesized and cationic liposomes. However, how to further enhance the tumor-targeting and cellular uptake of NPs have been great challenges in cancer therapy. It was reported that FR beta could be selectively augmented by all-trans retinoic acid (ATRA). Herein, we demonstrated the enhanced active tumor-targeting of FA-modified siRNA-loaded biomimetic albumin NPs (Lip-S@FBH) could be achieved by upregulating FR beta expression via ATRA NPs. And the systematic administration of ATRA NPs significantly promoted endocytosis and thereby increased the intracellular concentration of Lip-S@FBH. This strategy combined the FR beta amplification effect with the effective delivery of siRNA, is mostly desirable for the AML-targeting therapy.
机译:急性髓性白血病(AML)是血液恶性肿瘤最普遍和致命的疾病,尽管化疗和骨髓移植缺乏差。受益于在血液天动载体细胞系上试样表达的叶酸受体β(FRβ)的窄组织特异性,用叶酸(FA)改性的NPS已被广泛应用于交叉细胞膜屏障,用于AML的FR靶向疗法中。因此,由FRβ介导的仿生纳米颗粒(NPS)由白蛋白改性剂如前所以合成和阳离子脂质体进行。然而,如何进一步增强NPS的肿瘤靶向和细胞摄取在癌症治疗中是巨大的挑战。据报道,FRβ可以被全反式视黄酸(ATRA)选择性增强。在此,我们证明了通过通过ATRA NPS上调FRβ表达来实现FA改性的siRNA负载的生物摩擦白蛋白NPS(LIP-S @ FBH)的增强的活性肿瘤靶向。和ATRA NPS的系统施用显着促进了内吞作用,从而增加了唇缘的细胞内浓度。该策略将FRβ扩增效应与SiRNA有效递送组合,主要是为了AML靶向治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号